Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURWIN trial of durvalumab in poor-performance-status advanced urothelial cancer
2018-003027-11Phase 2Terminated
- Sponsor
- Consorzio Oncotech
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in transitional cell carcinoma (TCC), sponsored by Consorzio Oncotech. Primary endpoint: Overall response rate. Started May 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2018-003027-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003027-11.